[go: up one dir, main page]

Blankinship, 2005 - Google Patents

Advances in recombinant adeno-associated virus technology and implications for the treatment of Duchenne muscular dystrophy

Blankinship, 2005

Document ID
1110656701599435377
Author
Blankinship M
Publication year

External Links

Snippet

Recombinant adeno-associated virus (rAAV) based vectors have emerged as widely used gene transfer vehicles in a variety of gene therapy protocols. With recent engineering of truncated, yet highly functional dystrophin proteins (micro-dystrophins), rAAV vectors have …
Continue reading at search.proquest.com (other versions)

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA Viruses
    • C12N2750/00011—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA Viruses ssDNA Viruses
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals

Similar Documents

Publication Publication Date Title
Duan Micro-dystrophin gene therapy goes systemic in Duchenne muscular dystrophy patients
JP6453307B2 (en) Effective delivery of large genes by dual AAV vectors
JP7037574B2 (en) Composition useful for the treatment of spinal muscular atrophy
KR101835490B1 (en) Gene therapy for neurodegenerative disorders
US10301367B2 (en) Compositions and methods for treatment of muscular dystrophy
ES2291026T3 (en) VECTORS OF ADENOASOCIATED VIRUSES AND USES OF THE SAME.
JP5575486B2 (en) Synthetic mini / micro-dystrophin gene that restores nNOS in the muscle sheath
ES2745470T3 (en) AAV2 particle comprising a AAV2 capsid protein and a vector comprising a nucleic acid encoding a tripeptidyl peptidase 1 (TPP1) for the treatment of late childhood ceroid lipofuscinosis (LINCL) in a non-rodent mammal by intraventricular injection or administration icv
ES2826384T3 (en) Gene therapy for eye disorders
JP2021521152A (en) Rescue of Potential Opening Sodium Channels in Inhibitory Neurons
ES2835032T3 (en) Gene therapy for the treatment of a retinal cone cell disease
US12467066B2 (en) Compositions and methods for treating retinal disorders
CN117305367A (en) Double AAV vector system for expressing full-length otodontin and application thereof
BR112021002566A2 (en) gene sequence of recombinant human mitochondrial dynein type ii gtpase and its uses
TW202003052A (en) Compositions and methods for treating macular dystrophy
US20230295654A1 (en) Methods and compositions for treatment of fragile x syndrome
JP2023510784A (en) Methods and compositions for delivering immunotherapeutic agents across the blood-brain barrier to treat brain tumors
CN112601454B (en) Compositions and methods for treating Duchenne muscular dystrophy
JP2022548270A (en) Compositions and methods for the treatment of Friedreich's ataxia
Blankinship Advances in recombinant adeno-associated virus technology and implications for the treatment of Duchenne muscular dystrophy
CN121057823A (en) Methods of modifying neurons in vivo to treat and/or prevent Amyotrophic Lateral Sclerosis (ALS)
US20140155471A1 (en) Treating neurological disease or injury with a dynamin-related protein 1 (drp1) encoding nucleic acid
CN117377771A (en) carrier system
JP2022523038A (en) One-step gene therapy for Duchenne muscular dystrophy via gene replacement and anti-inflammatory
JP2021520231A (en) Compositions and methods for the treatment of Stargart's disease